Document Detail

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.
MedLine Citation:
PMID:  1586634     Owner:  NLM     Status:  MEDLINE    
In a Phase I study fosquidone was administered to 23 patients (15 female, 8 male; mean age 53.6 years) with various solid tumours. Increasing doses (50-325 mg/m2) were given intravenously three times a week for 3 weeks. The MTD was established a 325 mg/m2 dose, the dose limiting factor being phlebitis in two of three patients. The other main side-effects were headache (9 patients), pain (11 patients) and nausea and vomiting (16 patients). The majority of these were mild (WHO grade 1-2), but two patients reported WHO grade 3 and 4 pain. There was no clear relationship between dose, severity and frequency of side-effects. Four tumour regressions (three minor and one partial response) were achieved at varying dose levels (50, 100, 160 and 325 mg/m2) in patients with different tumours (laryngeal, colorectal and lung). The recommended dose for Phase II studies is 250 mg/m2 given intravenously three times a week for 3 week.
A S Planting; M E van der Burg; G Stoter; P Beranek; J Verweij
Related Documents :
21675044 - Advanced esophageal cancer with situs inversus totalis successfully treated with chemor...
21761354 - Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and li...
2199624 - Phase ii trial of serratia marcescens extract in recurrent malignant astrocytoma.
7912524 - Phase ii evaluation of taxol in advanced head and neck cancer: an eastern cooperative o...
9885604 - Metastatic head and neck cancer: role and usefulness of fdg pet in locating occult prim...
1711994 - Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis inser...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical oncology (Royal College of Radiologists (Great Britain))     Volume:  4     ISSN:  0936-6555     ISO Abbreviation:  Clin Oncol (R Coll Radiol)     Publication Date:  1992 May 
Date Detail:
Created Date:  1992-06-22     Completed Date:  1992-06-22     Revised Date:  2008-03-10    
Medline Journal Info:
Nlm Unique ID:  9002902     Medline TA:  Clin Oncol (R Coll Radiol)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  171-3     Citation Subset:  IM    
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Clinical Protocols
Drug Administration Schedule
Drug Evaluation
Headache / chemically induced
Injections, Intravenous
Isoquinolines / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Nausea / chemically induced
Neoplasms / drug therapy*
Organophosphorus Compounds*
Phlebitis / chemically induced
Remission Induction
Vomiting / chemically induced
Reg. No./Substance:
0/Antineoplastic Agents; 0/Isoquinolines; 0/Organophosphorus Compounds; 114517-02-1/fosquidone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Para-aortic nodal irradiation for early stage testicular seminoma.
Next Document:  An audit of travel and waiting times for outpatient radiotherapy.